Please cite this article in press Jay Vilas Giri et al., Artificial Intelligence (AI) Use In Drug Discovery, Indo Am. J. P. Sci, 2025; 12(12).

1. Paul SM et al. (2010). How to improve R&D productivity: the pharmaceutical industry’s grand challenge. Nature Reviews Drug Discovery, 9(3): 203–214.
2. Hughes JP et al. (2011). Principles of early drug discovery. British Journal of Pharmacology, 162(6): 1239–1249.
3. Waring MJ et al. (2015). An analysis of the attrition of drug candidates from four major pharmaceutical companies. Nature Reviews Drug Discovery, 14(7): 475–486.
4. Chen H et al. (2018). The rise of deep learning in drug discovery. Drug Discovery Today, 23(6): 1241–1250.
5. Vamathevan J et al. (2019). Applications of machine learning in drug discovery and development. Nature Reviews Drug Discovery, 18(6): 463–477.
6. Zhavoronkov A et al. (2019). Deep learning enables rapid identification of potent DDR1 kinase inhibitors. Nature Biotechnology, 37(9): 1038–1040.
7. Jiang D et al. (2021). Graph neural networks for drug discovery and development. Chemical Reviews, 121(16): 10073–10141.
8. Segler MH et al. (2018). Generating focused molecule libraries for drug discovery with recurrent neural networks. ACS Central Science, 4(1): 120–131.
9. Ekins S et al. (2020). Repurposing approved drugs as therapeutics for emerging viral diseases using AI. Drug Discovery Today, 25(9): 1564–1573.
10. Beck BR et al. (2020). Predicting commercially available antiviral drugs that may act on SARS-CoV-2 main protease using deep learning. Computers in Biology and Medicine, 125: 103827.
11. Jumper J et al. (2021). Highly accurate protein structure prediction with AlphaFold. Nature, 596(7873): 583–589.
12. Walters WP & Murcko MA (2020). Assessing the impact of generative AI on medicinal chemistry. Journal of Medicinal Chemistry, 63(21): 12564–12574.
13. Schneider G (2022). Automating drug discovery. Nature Reviews Drug Discovery, 21(9): 681–682. 14. Santos R et al. (2017). A comprehensive map of molecular drug targets. Nature Reviews Drug Discovery, 16(1): 19–34.
14. Cook D et al. (2014). Lessons learned from the fate of AstraZeneca’s drug pipeline: a five- dimensional framework. Nature Reviews Drug Discovery, 13(6): 419–431.
15. Chen H et al. (2018). The rise of deep learning in drug discovery. Drug Discovery Today, 23(6): 1241–1250.
16. Mayr A et al. (2018). Large-scale comparison of machine learning methods for drug target
prediction on ChEMBL. Chemical Science, 9(24): 5441–5451.
17. Li B et al. (2020). Genome-wide association studies aided by artificial intelligence reveal novel disease-associated loci. Nature Communications, 11(1): 5632.
18. Ching T et al. (2018). Opportunities and obstacles for deep learning in biology and medicine. Journal of the Royal Society Interface, 15(141): 20170387.
19. Sun J et al. (2021). Deep learning for cancer genomics and multi-omics integration. Nature Reviews Genetics, 22(12): 812–829.
20. Zitnik M et al. (2018). Modeling polypharmacy side effects with graph convolutional networks. Bioinformatics, 34(13): i457–i466.
21. Guney E et al. (2016). Network-based in silico drug efficacy screening. Nature Communications, 7(1): 10331.
22. Smith JS et al. (2020). AI in target validation: integrating data-driven and experimental approaches. Frontiers in Pharmacology, 11: 577.
23. Xu Y et al. (2022). AI-assisted predictive toxicology in drug discovery. Computational and Structural Biotechnology Journal, 20: 1526–1538.
24. Doench JG (2018). Am I ready for CRISPR? AI-based predictive models for guide RNA design. Nature Biotechnology, 36(12): 1141–1143.
25. Pearl J (2019). The seven tools of causal inference, with reflections on machine learning. Communications of the ACM, 62(3): 54–60.
26. Brown N et al. (2020). BenevolentAI’s approach to target identification using knowledge graphs. Drug Discovery Today, 25(9): 1569–1575.
27. Zhavoronkov A et al. (2020). AI-driven identification of fibrosis targets and drug candidates. Nature Biotechnology, 38(8): 965–970.
28. Ferrucci D et al. (2017). IBM Watson: Cognitive computing in healthcare and life sciences. AI Magazine, 38(1): 77–91.
29. Jumper J et al. (2021). Highly accurate protein structure prediction with AlphaFold. Nature, 596(7873): 583–589.
30. Hopkins AL et al. (2021). Exscientia and AstraZeneca: collaborative AI-driven drug discovery in oncology. Drug Discovery Today, 26(11): 2733–2740.
31. Beam AL & Kohane IS (2018). Big data and machine learning in health care. JAMA, 319(13): 1317–1318.
32. Samek W et al. (2019). Explainable artificial intelligence: understanding, visualizing, and interpreting deep learning models. IT Professional, 21(4): 82–89.
33. Chen M et al. (2023). Federated and explainable AI for precision drug discovery. Nature Machine Intelligence, 5(4): 312–325.
34. Schneider G (2022). Automating drug discovery. Nature Reviews Drug Discovery, 21(9): 681–682.
35. Schneider G & Fechner U. (2005). Computer-based de novo design of drug-like molecules. Nature Reviews Drug Discovery, 4(8): 649–663.
36. Walters WP et al. (2018). Machine learning for chemical discovery. Nature Reviews Chemistry, 2(10): 0098.
37. Zhavoronkov A et al. (2019). Deep learning enables rapid identification of potent DDR1 kinase inhibitors. Nature Biotechnology, 37(9): 1038–1040.
38. Popova M et al. (2018). Deep reinforcement learning for de novo drug design. Scientific Reports, 8: 8786.
39. Segler MH et al. (2018). Generating focused molecule libraries for drug discovery with recurrent neural networks. ACS Central Science, 4(1): 120–131.
40. Gómez-Bombarelli R et al. (2018). Automatic chemical design using a data-driven continuous representation of molecules. ACS Central Science, 4(2): 268–276.
41. Olivecrona M et al. (2017). Molecular de-novo design through deep reinforcement learning. Journal of Cheminformatics, 9(1): 48.
42. Stokes JM et al. (2020). A deep learning approach to antibiotic discovery. Cell, 180(4): 688–702.e13.
43. Jin W et al. (2020). Junction tree variational autoencoder for molecular graph generation. ICLR.
44. Chen H et al. (2020). AI in drug design and discovery: methods, applications, and future directions. Briefings in Bioinformatics, 21(5): 1919–1933.
45. Vamathevan J et al. (2019). Applications of machine learning in drug discovery and development. Nature Reviews Drug Discovery, 18(6): 463–477.
46. Yang K et al. (2019). Analyzing learned molecular representations for property prediction. Journal of Chemical Information and Modeling, 59(8): 3370–3388.
47. Goh GB et al. (2017). Chemception: a deep neural network with minimal chemistry
knowledge matches the performance of expert-developed QSAR/QSPR models. ACS Central Science, 3(8): 852–859.
48. Kotsias P et al. (2020). Direct steering of de novo molecular generation with descriptor conditional recurrent neural networks. Nature Machine Intelligence, 2: 254–265.
49. Chen C et al. (2020). MolGAN: An implicit generative model for small molecular graphs. ICML Workshop.
50. Gómez-Bombarelli R et al. (2016). Design of efficient molecular OLEDs by virtual screening and experiment. Nature Materials, 15(10): 1120–1127.
51. Altae-Tran H et al. (2017). Low data drug discovery with one-shot learning. ACS Central Science, 3(4): 283–293.
52. Elton DC et al. (2019). Deep learning for molecular design—a review of the state of the art. Molecular Systems Design & Engineering, 4(4): 828–849.
53. Kadurin A et al. (2017). druGAN: generative adversarial autoencoder model for de novo generation of molecules. Molecular Pharmaceutics, 14(9): 3098–3104.
54. Winter R et al. (2019). Efficient multi-objective molecular optimization in a continuous latent space. Chemical Science, 10(34): 8016–8024. 56. Ekins S et al. (2019). Exploiting machine learning for end-to-end drug discovery and development. Nature Materials, 18: 435–443.
55. Zhang L et al. (2020). Artificial intelligence in preclinical drug development. Drug Discovery Today, 25(5): 848–858.
56. Wu Z et al. (2018). MoleculeNet: a benchmark for molecular machine learning. Chemical Science, 9: 513–530.
57. Hou T et al. (2011). ADME evaluation in drug discovery: 15 years’ experience. Current Topics in Medicinal Chemistry, 11(4): 365–380.
58. Kirchmair J et al. (2015). Computational prediction of metabolism: advances in the field. Drug Discovery Today, 20(9): 1153–1160.
59. Yang K et al. (2019). Analyzing learned molecular representations for property prediction. Journal of Chemical Information and Modeling, 59(8): 3370–3388.
60. Mayr A et al. (2016). DeepTox: Toxicity prediction using deep learning. Frontiers in Environmental Science, 3: 80.
61. Liu R et al. (2015). Toxicity prediction using deep learning models. Journal of Chemical
Information and Modeling, 55(2): 328–342.
62. Kadurin A et al. (2017). druGAN: generative adversarial autoencoder for de novo generation of safe molecules. Molecular Pharmaceutics, 14(9): 3098–3104.
63. Chen H et al. (2020). AI in drug design and discovery: methods, applications, and future directions. Briefings in Bioinformatics, 21(5): 1919–1933.
64. Mayr A et al. (2016). DeepTox: Toxicity prediction using deep learning. Frontiers in Environmental Science, 3: 80.
65. Xiong G et al. (2021). ADMETLab 2.0: an online platform for accurate and comprehensive predictions of ADMET properties. Nucleic Acids Research, 49(W1): W5–W14.
66. Banerjee P et al. (2018). ProTox-II: a webserver for the prediction of toxicity of chemicals. Nucleic Acids Research, 46(W1): W257–W263.
67. Zhavoronkov A et al. (2020). Artificial intelligence for preclinical toxicity prediction. Nature Reviews Drug Discovery, 19(2): 82–100.
68. Vamathevan J et al. (2019). Applications of machine learning in drug discovery and development. Nature Reviews Drug Discovery, 18(6): 463–477.
69. \Wu K et al. (2020). AI-enabled drug discovery for reducing preclinical costs. Drug Discovery Today, 25(9): 1607–1615.
70. Chen Y et al. (2021). Machine learning in toxicity prediction: a review. Chemical Research in Toxicology, 34(3): 525–540.
71. Zhavoronkov A et al. (2020). AI in preclinical evaluation and toxicity prediction. Drug Discovery Today, 25(9): 1549–1560.
72. Fang H et al. (2019). Challenges and opportunities in AI-based toxicity prediction. Frontiers in Pharmacology, 10: 345.
73. Jiménez-Luna J et al. (2020). Drug discovery with explainable AI: promises and challenges. Nature Machine Intelligence, 2: 573–584.
74. Wong CH et al. (2019). Estimating clinical trial success rates and related parameters. Biostatistics, 20(2): 273–286.
75. Esteva A et al. (2019). A guide to deep learning in healthcare. Nature Medicine, 25: 24– 29.
76. Topol EJ. (2019). High-performance medicine: the convergence of human and artificial intelligence. Nature Medicine, 25: 44–56.
77. Rajkomar A et al. (2019). Machine learning in medicine. New England Journal of Medicine, 380: 1347–1358.
78. Wong CH et al. (2019). Predicting clinical trial outcomes using machine learning. Journal of Translational Medicine, 17: 174.
79. Berry SM et al. (2010). Bayesian adaptive methods for clinical trials. CRC Press, 1st Edition.
80. Cheng J et al. (2020). AI-driven patient recruitment in clinical trials. Frontiers in Digital Health, 2: 584456.
81. Scott IC et al. (2018). Machine learning for patient recruitment in clinical trials. Drug Discovery Today, 23(11): 1863–1870.
82. Kourou K et al. (2015). Machine learning applications in cancer prognosis and prediction. Computational and Structural Biotechnology Journal, 13: 8–17.
83. Topol EJ. (2019). Precision medicine and AI in clinical trials. Nature Medicine, 25: 44– 56.
84. Lee J et al. (2020). AI-based biomarker discovery for patient stratification. Journal of Clinical Oncology, 38(15): 1725–1734.
85. Cho H et al. (2021). Clustering-based patient stratification using AI. Bioinformatics, 37(6): 784–791.
86. Miotto R et al. (2018). Deep patient: an unsupervised representation to predict the future of patients from EHRs. Scientific Reports, 8: 113.
87. Chen R et al. (2021). AI in oncology clinical trials: patient stratification and outcomes. Nature Reviews Clinical Oncology, 18: 463–480.
88. IBM Watson Health. (2019). Clinical trial matching solutions. IBM.
89. Deep 6 AI. (2020). Accelerating patient recruitment through AI. Deep 6 AI Whitepaper.
90. BenevolentAI. (2020). AI-driven drug discovery for COVID-19. Nature Biotechnology, 38: 123–127.
91. Tempus. (2021). AI-powered patient stratification for oncology trials. Tempus Insights.
92. Liu Y et al. (2019). AI-assisted clinical trial optimization. Journal of Biomedical Informatics, 98: 103272.
93. Collins FS & Varmus H. (2015). A new initiative on precision medicine. New England Journal of Medicine, 372: 793–795.
94. Lazarou J et al. (1998). Incidence of adverse drug reactions in hospitalized patients. JAMA, 279: 1200–1205.
95. Wang F et al. (2020). Artificial intelligence in pharmacovigilance. Expert Opinion on Drug Safety, 19(4): 377–388.
96. Harpaz Retal. (2014). Mining biomedical literature and social media for pharmacovigilance. Drug Safety, 37: 171–182.
97. Li X et al. (2019). NLP for adverse event detection from clinical notes. Journal of Biomedical Informatics, 97: 103253.
98. Sarker A et al. (2015). Social media mining for drug safety surveillance. Journal of Biomedical Informatics, 54: 202–212.
99. DuMouchel W. (1999). Bayesian data mining in large frequency tables, with an application to the FDA spontaneous reporting system. American Statistician, 53: 177–190.
Tatonetti NP et al. (2012). Data-driven prediction of drug effects and interactions. Science Translational Medicine, 4(125): 125ra31.
100.Li J et al. (2020). Deep learning for adverse drug reaction signal detection. Artificial Intelligence in Medicine, 103: 101805.
101. Vilar S et al. (2018). Drug-drug interaction prediction using chemical, pharmacological, and network features. Bioinformatics, 34(13): i857–i865.
102. Ryu JY et al. (2018). Deep learning improves prediction of drug-drug and drug-food interactions. Bioinformatics, 34(17): i500–i508.
103. Xu R et al. (2021). AI in real-world evidence for drug safety. Pharmacoepidemiology and Drug Safety, 30(4): 451–462.
104. Li J et al. (2018). DeepADE: a deep learning approach for adverse drug event extraction. Bioinformatics, 34(17): i603–i611.
105.Sarker A et al. (2016). MedWatcher Social: an AI-powered system for monitoring adverse drug events on social media. Drug Safety, 39: 433–441.
106.Harpaz R et al. (2012). Performance of pharmacovigilance signal detection algorithms for the FDA adverse event reporting system. Drug Safety, 35: 789–801.
107. Chen R et al. (2019). Automated pharmacovigilance using AI techniques. Journal of Biomedical Informatics, 94: 103182.
108. Searle T et al. (2019). Integrating heterogeneous data sources for pharmacovigilance. Pharmacoepidemiology and Drug Safety, 28: 1289–1297.
109. DuMouchel W et al. (2013). Bayesian data mining for proactive safety monitoring. Clinical Pharmacology & Therapeutics, 93: 542–550.
110. Harpaz R et al. (2012). Challenges and opportunities in AI-based pharmacovigilance. Drug Safety, 35: 93–101. 116. Mak KK & Pichika MR. (2019). Artificial intelligence in drug development: present status and future prospects. Drug Discovery Today, 24(3): 773– 780.
111. Vamathevan J et al. (2019). Applications of AI in drug discovery and development. Nature Reviews Drug Discovery, 18: 463–477.
112. Chen H et al. (2018). The rise of AI in drug discovery. Drug Discovery Today, 23(6): 1241–1250.
113. Zhang A et al. (2020). Multi-omics integration for AI-driven drug discovery. Briefings in Bioinformatics, 21(6): 2030–2046.
114. Hasin Y et al. (2017). Multi-omics approaches to disease. Genome Biology, 18: 83.
115. Viceconti M et al. (2019). In silico clinical trials: how computer simulation will transform the biomedical industry. International Journal of Clinical Trials, 6(2): 25–33.
116. Razavian N & Sontag D. (2015). Temporal convolutional models for patient-specific predictions. AMIA Annual Symposium Proceedings, 2015: 277–286.
117. Sanchez-Lengeling B & Aspuru-Guzik A. (2018). Inverse molecular design using machine learning: Generative models for matter engineering. Science, 361: 360–365.
118. Olivecrona M et al. (2017). Molecular de novo design through deep reinforcement learning. Journal of Cheminformatics, 9: 48.
119. Topol EJ. (2019). High-performance medicine: the convergence of human and artificial intelligence. Nature Medicine, 25: 44–56.
120. Beam AL & Kohane IS. (2018). Big data and machine learning in health care. JAMA, 319(13): 1317–1318.
121. Rumsfeld JS et al. (2016). Big data analytics to improve cardiovascular care. Circulation,
133: 127–145.
122. Wang F et al. (2020). AI-enabled real-time monitoring in healthcare. Journal of Healthcare Informatics Research, 4: 23–42.
123. Chen R et al. (2019). Challenges in data-driven drug discovery. Briefings in Bioinformatics, 20(4): 1376–1386.
124. Beam AL et al. (2020). Clinical implications of AI in healthcare: biases and limitations. Journal of the American Medical Association, 323: 113–114.
125. Holzinger A et al. (2017). What do we need to build explainable AI systems for the medical domain? arXiv preprint, arXiv:1712.09923.
126. Morley J et al. (2020). Ethics of AI in healthcare: a mapping review. Social Science & Medicine, 260: 113172.
127. van der Schaar M et al. (2021). Opportunities and challenges for AI in healthcare. Nature Medicine, 27: 1–11.
128. Jiang F et al. (2017). Artificial intelligence in healthcare: past, present and future. Stroke and Vascular Neurology, 2: 230–243.
129. Li T et al. (2020). Federated learning: challenges, methods, and future directions. IEEE Signal Processing Magazine, 37(3): 50–60. 136. Mak KK & Pichika MR. (2019). Artificial intelligence in drug development: present status and future prospects. Drug Discovery Today, 24(3): 773–780.
130. Vamathevan J et al. (2019). Applications of AI in drug discovery and development. Nature Reviews Drug Discovery, 18: 463–477.
131. Chen H et al. (2018). The rise of AI in drug discovery. Drug Discovery Today, 23(6): 1241–1250.
134139. Topol EJ. (2019). High-performance medicine: the convergence of human and artificial intelligence. Nature Medicine, 25: 44–56.
135. Zhang A et al. (2020). Multi-omics integration for AI-driven drug discovery. Briefings in Bioinformatics, 21(6): 2030–2046.
136. Wang F et al. (2020). AI-enabled real-time monitoring in healthcare. Journal of Healthcare Informatics Research, 4: 23–42.
137. Jiang F et al. (2017). Artificial intelligence in healthcare: past, present and future. Stroke and Vascular Neurology, 2: 230–243.
138. Sanchez-Lengeling B & Aspuru-Guzik A. (2018). Inverse molecular design using machine learning: Generative models for matter engineering. Science, 361: 360–365.
139. Viceconti M et al. (2019). In silico clinical trials: how computer simulation will transform the biomedical industry. International Journal of Clinical Trials, 6(2): 25–33.
140. Hasin Y et al. (2017). Multi-omics approaches to disease. Genome Biology, 18: 83.
141. Zhavoronkov A et al. (2019). Deep learning enables rapid identification of potential drug repurposing candidates. Nature Biotechnology, 37: 1038–1040.
142. Chen R et al. (2019). Challenges in data-driven drug discovery. Briefings in Bioinformatics, 20(4): 1376–1386.148. Harpaz R et al. (2014). Mining biomedical literature and social media for pharmacovigilance. Drug Safety, 37: 171–182.
143. Vamathevan J et al. (2019). Applications of AI in drug discovery and development. Nature Reviews Drug Discovery, 18: 463–477.
144. Chen H et al. (2018). The rise of AI in drug discovery. Drug Discovery Today, 23(6): 1241–1250.
145. Zhavoronkov A et al. (2019). Deep learning enables rapid identification of potential drug repurposing candidates. Nature Biotechnology, 37: 1038–1040.
146. Hasin Y et al. (2017). Multi-omics approaches to disease. Genome Biology, 18: 83. 147152. Beam AL & Kohane IS. (2018). Big data and machine learning in health care. JAMA,319(13): 1317–1318.
148. Holzinger A et al. (2017). What do we need to build explainable AI systems for the medical domain? arXiv preprint, arXiv:1712.09923.
149. Sanchez-Lengeling B & Aspuru-Guzik A. (2018). Inverse molecular design using machine learning: Generative models for matter engineering. Science, 361: 360–365.
150. Viceconti M et al. (2019). In silico clinical trials: how computer simulation will transform the biomedical industry. International Journal of Clinical Trials, 6(2): 25–33.
151. Mak KK & Pichika MR. (2020). Current challenges and future directions in AI applications for drug discovery. Drug Discovery Today, 25(1): 13–22.